GCTKHealthcare · Medical DevicesTicker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 10 of 100 as at 12 Oct 2026 — in the weakest quartile.
Consensus tells you what everyone already believes. The model scores GlucoTrack, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (100): Smaller than most of the companies we track.
Issuance (2): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on GCTK, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. GCTK appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 12 Oct 2026, GlucoTrack, Inc. returned −99.0% against +20.4% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 73% of US stocks
Cheaper than 96% of US stocks
Cheaper than 62% of US stocks
Higher than 32% of US stocks
Higher than 30% of US stocks
Higher than 3% of US stocks
Higher than 1% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
GlucoTrack, Inc. has a market value of $1.0M and an enterprise value of $1.6M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$15.9M.
Free cash flow in the twelve months to 30 June 2026: −$16.3M.
Trailing P/E: 0.1×.
Forward dividend yield: 0.00%, paying out 0% of earnings.
GlucoTrack, Inc. employs 15 people.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own GlucoTrack, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Glucotrack, Inc. announced the pricing of a $3 million public offering, as disclosed in a Business Wire release from its Rutherford, N.J. and La Jolla, Calif. locations.
Why it matters — A GCTK watcher would care because this capital raise may affect the company's share count and financial positioning going forward.
GlucoTrack shares traded sharply higher in pre-market trading after its subsidiary, Lokahi Therapeutics, announced its first external, fee-for-service partnership. The stock rose around 118% following the announcement.
Why it matters — This marks the first external fee-for-service partnership for GlucoTrack's subsidiary, signalling a potential new service-based revenue avenue for GCTK.
Lōkahi Therapeutics CEO Erik Emerson, who also serves as Glucotrack CEO, provided a strategic update covering progress on the LT-100 program, growth of the ai² platform, and clinical development priorities, along with a strategy to discover, advance, and monetize assets.
Why it matters — A GCTK watcher would care because this update outlines the strategic direction and development priorities of its CEO's leadership across the Lōkahi and Glucotrack programs.
Glucotrack announced an $11.5 million convertible note financing, comprising new capital and a note rollover, to support its strategic growth. The announcement was made via Business Wire from the company's Rutherford, N.J. and La Jolla, Calif. locations.
Why it matters — A GCTK watcher would care because the new financing provides the company with additional capital to fund its strategic growth initiatives.
Glucotrack, Inc. announced a 1-for-15 reverse stock split effective August 31, 2026, to support Nasdaq listing compliance.
Why it matters — A GCTK watcher would care because the reverse split is intended to help the company maintain continued compliance with Nasdaq listing requirements.
As at 12 Oct 2026, GlucoTrack, Inc. ranks 10 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (100 of 100).
No analyst covering GlucoTrack, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for GCTK are extrapolating price history, which says nothing about the business.
GlucoTrack, Inc. returned -99.0% over the 12 months to 12 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
GlucoTrack Inc. is a medical technology company focused on diabetes monitoring solutions.
The most recent item we track (Business Wire, 24 Sept 2026): "Glucotrack, Inc. Announces Pricing of $3 Million Public Offering". Glucotrack, Inc. announced the pricing of a $3 million public offering, as disclosed in a Business Wire release from its Rutherford, N.J. and La Jolla, Calif. locations.
GlucoTrack Inc. is a medical technology company focused on diabetes monitoring solutions. GlucoTrack Inc. develops devices and systems designed to measure blood glucose levels for people living with diabetes, with an emphasis on continuous monitoring and reduced reliance on traditional finger-stick testing. Its current work centers on non-invasive glucose monitoring technology and an investigational long-term implantable continuous blood glucose monitor intended for ongoing glycemic tracking. The company’s products and development programs are aimed at supporting patients with Type 1 diabetes, insulin-dependent Type 2 diabetes, and prediabetes, while also serving clinicians who manage these conditions. GlucoTrack Inc. operates within the healthcare equipment and medical device market, where glucose monitoring tools play a critical role in daily diabetes care and disease management. The company is headquartered in Rutherford, New Jersey.
CEO Mr. Erik C. Emerson · 15 employees · United States · https://glucotrack.com
